溶瘤病毒在肝细胞癌治疗中的研究现状及前景
摘要
关键词
全文:
PDF参考
[1]Oura K，Morishita A，Tani J，et al.Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma：
A Review[J/OL].International Journal of Molecular Sciences，2021，22（11）：5801.
[2]Chakraborty E，Sarkar D.Emerging Therapies for Hepatocellular Carcinoma（HCC）[J/OL].Cancers，2022，14（11）：2798.
[3]Goradel N H，Baker A T，Arashkia A，et al.Oncolytic virotherapy：Challenges and solutions[J/OL].Current Problems in Cancer，
2021，45（1）：100639.
[4]Davola M E，Mossman K L.Oncolytic viruses：how “lytic” must they be for therapeutic efficacy?[J/OL].OncoImmunology，2019，
8（6）：e1581528.
[5]Oncolytic Viruses as Nanomedicines against the Tumor Microenvironment[J/OL].Biointerface Research in Applied Chemistry，2021，
11（6）：14825-14852.
[6]Geevarghese S K，Geller D A，De Haan H A，et al.Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with
Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver[J/OL].Human Gene Therapy，2010，21（9）：1119-1128.
[7]Heo J，Liang J D，Kim C W，et al.Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced
liver cancer：Phase I clinical trial[J/OL].Molecular Therapy，2023，31（7）：2077-2088.
[8]Park B H，Hwang T，Liu T C，et al.Use of a targeted oncolytic poxvirus，JX-594，in patients with refractory primary or metastatic liver
cancer：a phase I trial[J/OL].The Lancet Oncology，2008，9（6）：533-542.
(7 摘要 Views, 38 PDF Downloads)
Refbacks
- 当前没有refback。